Your browser doesn't support javascript.
loading
A novel method for strict intranasal delivery of non-replicating RSV vaccines in cotton rats and non-human primates.
Citron, Michael P; Patel, Manishkumar; Purcell, Mona; Lin, Shu-An; Rubins, Daniel J; McQuade, Paul; Callahan, Cheryl; Gleason, Alexa; Petrescu, Ioan; Knapp, Walter; Orekie, Chinedu; Chamarthy, Sai; Wen, Zhiyun; Touch, Sinoeun; Pine, Matthew; Fontenot, Jane; Douglas, Cameron; Liang, Xiaoping; Espeseth, Amy S.
Afiliación
  • Citron MP; Infectious Disease/Vaccines, Merck & Co., Inc., Kenilworth, NJ 07033, United States. Electronic address: michael_citron@merck.com.
  • Patel M; Translational Imaging Biomarkers, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Purcell M; Translational Imaging Biomarkers, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Lin SA; Translational Imaging Biomarkers, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Rubins DJ; Translational Imaging Biomarkers, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • McQuade P; Translational Imaging Biomarkers, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Callahan C; Infectious Disease/Vaccines, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Gleason A; Translational Imaging Biomarkers, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Petrescu I; Safety Assessment and Laboratory Animal Sciences, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Knapp W; Safety Assessment and Laboratory Animal Sciences, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Orekie C; Biopharmaceutics & Specialty DF/Development, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Chamarthy S; Biopharmaceutics & Specialty DF/Development, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Wen Z; Infectious Disease/Vaccines, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Touch S; Infectious Disease/Vaccines, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Pine M; Infectious Disease/Vaccines, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Fontenot J; The University of Louisiana New Iberia Research Center, New Iberia, LA 70560, United States.
  • Douglas C; Infectious Disease/Vaccines, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Liang X; Infectious Disease/Vaccines, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
  • Espeseth AS; Infectious Disease/Vaccines, Merck & Co., Inc., Kenilworth, NJ 07033, United States.
Vaccine ; 36(20): 2876-2885, 2018 05 11.
Article en En | MEDLINE | ID: mdl-29599087
ABSTRACT
Respiratory syncytial virus (RSV) is the most common viral cause of bronchiolitis and pneumonia in children twelve months of age or younger and a significant cause of lower respiratory disease in older adults. As various clinical and preclinical candidates advance, cotton rats (Sigmodon hispidus) and non-human primates (NHP) continue to play a valuable role in RSV vaccine development, since both animals are semi-permissive to human RSV (HRSV). However, appropriate utilization of the models is critical to avoid mis-interpretation of the preclinical findings. Using a multimodality imaging approach; a fluorescence based optical imaging technique for the cotton rat and a nuclear medicine based positron emission tomography (PET) imaging technique for monkeys, we demonstrate that many common practices for intranasal immunization in both species result in inoculum delivery to the lower respiratory tract, which can result in poor translation of outcomes from the preclinical to the clinical setting. Using these technologies we define a method to limit the distribution of intranasally administered vaccines solely to the upper airway of each species, which includes volume restrictions in combination with injectable anesthesia. We show using our newly defined methods for strict intranasal immunization that these methods impact the immune responses and efficacy observed when compared to vaccination methods resulting in distribution to both the upper and lower respiratory tracts. These data emphasize the importance of well-characterized immunization methods in the preclinical assessment of intranasally delivered vaccine candidates.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Administración Intranasal / Chlorocebus aethiops / Sigmodontinae / Virus Sincitial Respiratorio Humano / Infecciones por Virus Sincitial Respiratorio / Vacunas contra Virus Sincitial Respiratorio Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Vaccine Año: 2018 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Administración Intranasal / Chlorocebus aethiops / Sigmodontinae / Virus Sincitial Respiratorio Humano / Infecciones por Virus Sincitial Respiratorio / Vacunas contra Virus Sincitial Respiratorio Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Vaccine Año: 2018 Tipo del documento: Article